A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Phase 2 Active not recruiting 170 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

Timeline

Start: 2022-02-17
Primary completion: 2026-10-01
Completion: 2026-10-02

Publications

Tzoumas N, Riding G, Williams MA, Steel DH. Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iptacopan	Small molecule	—	Oral

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Summary

Timeline

Publications

Drugs

Indications